Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Result of AGM

24th May 2021 10:48

RNS Number : 5883Z

4d Pharma PLC

24 May 2021

4D pharma plc

(the "Company" or "4D")

Result of AGM

At the annual general meeting of 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, held earlier today, all resolutions put to shareholders were duly passed.

The full text of each resolution was included in the notice of the meeting, which was posted to shareholders on 15 April 2021, and is available on the Company's website www.4dpharmaplc.com.

The results for the resolutions will shortly be available on the Shareholder Information section of Company's website, www.4dpharmaplc.com.

For further information please contact:

4D pharma plc
Duncan Peyton, Chief Executive Officer [email protected]	+ 44 (0)113 895 0130
N+1 Singer Advisory LLP - Nominated Adviser and Joint Broker	+44 (0) 20 7496 3000
Phil Davies/Iqra Amin (Corporate Finance) Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker	+44 (0)20 7332 2500
Dominic Wilson / Phil Walker

About 4D pharma plc

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programmes, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalised with COVID-19, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programmes include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGGCGDUISDDGBS

Related Shares:

FTSE 100 Latest

Value8,809.74

Change53.53